The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19

Detalhes bibliográficos
Autor(a) principal: Silva, Eduarda Luiza Maciel da
Data de Publicação: 2021
Outros Autores: Silva, Guilherme Vinício de Sousa, Fonseca, Graciela Soares, Arias, Cesar Andres Diaz
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/16505
Resumo: Pandemy caused by the new coronavirus (SAR-CoV-2) represents a challenge for public health worldwide, due to the high transmissibility of the virus, consequent overload of health systems and large number of deaths. Studies and research are being carried out in order to identify safe and effective therapeutic alternatives for COVID-19, a disease caused by SAR-CoV-2, since there is still no consensus or scientific evidence that any drug can suppress viral excretion without causing massive side effects to the patient. In this perspective, some drugs are being used in clinical practice and, among them, is the combination of Lopinavir with Ritonavir, antiretroviral drugs commonly used in HIV treatment. The aim of this narrative review is to analyze the use of the Lopinavir/Ritonavir combination as a therapeutic alternative for COVID-19. The results indicate that the Lopinavir/Ritonavir combination has been used as an adjunctive treatment in cases of COVID-19, usually combined with other medications. Studies suggest that this combination does not interfere with ICU time and that the percentage of deaths is not significant. When applied at the onset of symptoms, these medications cause reduced viral excretion and fewer intubations. However, there is a contradiction regarding this, as some studies suggest an increase in viral excretion in patients who received these drugs. It reinforces the need to intensify studies related to treatment for COVID-19 in order to generate conclusive data so that medications can be used effectively and safely.
id UNIFEI_7371b09dcfbf0b3d4b08d5dba03160a0
oai_identifier_str oai:ojs.pkp.sfu.ca:article/16505
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19El uso de Lopinavir y Ritonavir como alternativa terapéutica al COVID-19O uso de Lopinavir e Ritonavir como alternativa terapêutica para a COVID-19Coronavirus InfectionsLopinavirRitonavirDrug therapy.Infecciones por CoronavirusLopinavirRitonavirQuimioterapia.Infecções por CoronavirusLopinavirRitonavirTratamento farmacológico.Pandemy caused by the new coronavirus (SAR-CoV-2) represents a challenge for public health worldwide, due to the high transmissibility of the virus, consequent overload of health systems and large number of deaths. Studies and research are being carried out in order to identify safe and effective therapeutic alternatives for COVID-19, a disease caused by SAR-CoV-2, since there is still no consensus or scientific evidence that any drug can suppress viral excretion without causing massive side effects to the patient. In this perspective, some drugs are being used in clinical practice and, among them, is the combination of Lopinavir with Ritonavir, antiretroviral drugs commonly used in HIV treatment. The aim of this narrative review is to analyze the use of the Lopinavir/Ritonavir combination as a therapeutic alternative for COVID-19. The results indicate that the Lopinavir/Ritonavir combination has been used as an adjunctive treatment in cases of COVID-19, usually combined with other medications. Studies suggest that this combination does not interfere with ICU time and that the percentage of deaths is not significant. When applied at the onset of symptoms, these medications cause reduced viral excretion and fewer intubations. However, there is a contradiction regarding this, as some studies suggest an increase in viral excretion in patients who received these drugs. It reinforces the need to intensify studies related to treatment for COVID-19 in order to generate conclusive data so that medications can be used effectively and safely.La pandemia provocada por el nuevo coronavirus (SAR-CoV-2) representa un desafío para la salud pública a nivel mundial, debido a la alta transmisibilidad del virus, la consiguiente sobrecarga de los sistemas de salud y la gran cantidad de muertes. Así, se están realizando estudios e investigaciones con el fin de identificar alternativas terapéuticas seguras y efectivas para COVID-19, una enfermedad causada por SAR-CoV-2, ya que aún no existe consenso o evidencia científica de que algún fármaco pueda inhibir la excreción viral. sin causar efectos secundarios masivos al paciente. En esta perspectiva, algunos fármacos se están utilizando en la práctica clínica y, entre ellos, se encuentra la combinación de Lopinavir con Ritonavir, fármacos antirretrovirales comúnmente utilizados en el tratamiento del VIH. El objetivo de esta revisión narrativa es analizar el uso de la combinación Lopinavir / Ritonavir como alternativa terapéutica para COVID-19. Los resultados indican que la combinación de Lopinavir / Ritonavir se ha utilizado como tratamiento adyuvante en casos de COVID-19, generalmente combinado con otros medicamentos. Los estudios sugieren que esta combinación no interfiere con el tiempo en la UCI y que el porcentaje de muertes no es significativo. Cuando se aplican al inicio de los síntomas, estos medicamentos reducen la excreción viral y provocan menos intubaciones. Sin embargo, existe una contradicción al respecto, ya que algunos estudios sugieren un aumento de la excreción viral en los pacientes que recibieron estos fármacos. Refuerza la necesidad de intensificar los estudios relacionados con el tratamiento del COVID-19 con el fin de generar datos concluyentes para que los medicamentos se puedan utilizar de forma eficaz y segura.A pandemia causada pelo novo coronavírus (SAR-CoV-2) representa um desafio para a saúde pública do mundo inteiro, em função da alta transmissibilidade do vírus, consequente sobrecarga dos sistemas de saúde e grande número de óbitos. Assim, estudos e pesquisas estão sendo realizados no intuito de identificar alternativas terapêuticas seguras e eficazes para a COVID-19, doença causada pelo SAR-CoV-2, visto que ainda não há um consenso nem evidência científica de que algum medicamento possa suprimir a excreção viral sem trazer massivos efeitos colaterais ao paciente. Nessa perspectiva, alguns fármacos estão sendo utilizados na prática clínica e, dentre eles, encontra-se a combinação do Lopinavir com o Ritonavir, antiretrovirais comumente utilizados no tratamento do HIV. O objetivo dessa revisão narrativa é analisar o uso da combinação Lopinavir/Ritonavir como alternativa terapêutica para a COVID-19. Os resultados indicam que a associação Lopinavir/Ritonavir tem sido utilizada como tratamento coadjuvante nos casos de COVID-19, normalmente combinada com outros medicamentos. Estudos sugerem que essa combinação não interfere no tempo de UTI e que a porcentagem de óbitos não é significativa. Quando aplicada no início dos sintomas, essas medicações causam redução na excreção viral e menor número de intubação. No entanto, há contradição referente a isso, já que alguns estudos sugerem aumento na excreção viral em pacientes que receberam esses medicamentos. Reforça-se a necessidade de intensificar os estudos relacionados ao tratamento para COVID-19 no sentido de gerar dados conclusivos para que as medicações possam ser utilizadas com eficácia e segurança.Research, Society and Development2021-06-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1650510.33448/rsd-v10i7.16505Research, Society and Development; Vol. 10 No. 7; e43410716505Research, Society and Development; Vol. 10 Núm. 7; e43410716505Research, Society and Development; v. 10 n. 7; e434107165052525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/16505/14991Copyright (c) 2021 Eduarda Luiza Maciel da Silva; Guilherme Vinício de Sousa Silva; Graciela Soares Fonseca; Cesar Andres Diaz Ariashttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Eduarda Luiza Maciel da Silva, Guilherme Vinício de Sousa Fonseca, Graciela Soares Arias, Cesar Andres Diaz 2021-07-18T21:07:03Zoai:ojs.pkp.sfu.ca:article/16505Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:37:02.055662Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
El uso de Lopinavir y Ritonavir como alternativa terapéutica al COVID-19
O uso de Lopinavir e Ritonavir como alternativa terapêutica para a COVID-19
title The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
spellingShingle The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
Silva, Eduarda Luiza Maciel da
Coronavirus Infections
Lopinavir
Ritonavir
Drug therapy.
Infecciones por Coronavirus
Lopinavir
Ritonavir
Quimioterapia.
Infecções por Coronavirus
Lopinavir
Ritonavir
Tratamento farmacológico.
title_short The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
title_full The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
title_fullStr The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
title_full_unstemmed The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
title_sort The use of Lopinavir and Ritonavir as a therapeutic alternative for COVID-19
author Silva, Eduarda Luiza Maciel da
author_facet Silva, Eduarda Luiza Maciel da
Silva, Guilherme Vinício de Sousa
Fonseca, Graciela Soares
Arias, Cesar Andres Diaz
author_role author
author2 Silva, Guilherme Vinício de Sousa
Fonseca, Graciela Soares
Arias, Cesar Andres Diaz
author2_role author
author
author
dc.contributor.author.fl_str_mv Silva, Eduarda Luiza Maciel da
Silva, Guilherme Vinício de Sousa
Fonseca, Graciela Soares
Arias, Cesar Andres Diaz
dc.subject.por.fl_str_mv Coronavirus Infections
Lopinavir
Ritonavir
Drug therapy.
Infecciones por Coronavirus
Lopinavir
Ritonavir
Quimioterapia.
Infecções por Coronavirus
Lopinavir
Ritonavir
Tratamento farmacológico.
topic Coronavirus Infections
Lopinavir
Ritonavir
Drug therapy.
Infecciones por Coronavirus
Lopinavir
Ritonavir
Quimioterapia.
Infecções por Coronavirus
Lopinavir
Ritonavir
Tratamento farmacológico.
description Pandemy caused by the new coronavirus (SAR-CoV-2) represents a challenge for public health worldwide, due to the high transmissibility of the virus, consequent overload of health systems and large number of deaths. Studies and research are being carried out in order to identify safe and effective therapeutic alternatives for COVID-19, a disease caused by SAR-CoV-2, since there is still no consensus or scientific evidence that any drug can suppress viral excretion without causing massive side effects to the patient. In this perspective, some drugs are being used in clinical practice and, among them, is the combination of Lopinavir with Ritonavir, antiretroviral drugs commonly used in HIV treatment. The aim of this narrative review is to analyze the use of the Lopinavir/Ritonavir combination as a therapeutic alternative for COVID-19. The results indicate that the Lopinavir/Ritonavir combination has been used as an adjunctive treatment in cases of COVID-19, usually combined with other medications. Studies suggest that this combination does not interfere with ICU time and that the percentage of deaths is not significant. When applied at the onset of symptoms, these medications cause reduced viral excretion and fewer intubations. However, there is a contradiction regarding this, as some studies suggest an increase in viral excretion in patients who received these drugs. It reinforces the need to intensify studies related to treatment for COVID-19 in order to generate conclusive data so that medications can be used effectively and safely.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-28
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/16505
10.33448/rsd-v10i7.16505
url https://rsdjournal.org/index.php/rsd/article/view/16505
identifier_str_mv 10.33448/rsd-v10i7.16505
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/16505/14991
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 7; e43410716505
Research, Society and Development; Vol. 10 Núm. 7; e43410716505
Research, Society and Development; v. 10 n. 7; e43410716505
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052825222512640

Registros relacionados